Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination

Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)

Adher D. Al Sayed, Mahmoud A. Elshenawy, Asma Tulbah, Taher Al-Tweigeri, Hazem Ghebeh

Saudi Arabia Department of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Am J Case Rep 2019; 20:1630-1635

DOI: 10.12659/AJCR.918770

Available online: 2019-11-06

Published: 2019-11-06


BACKGROUND: Metaplastic breast cancer (MPBC) is a rare subtype of breast cancer that is difficult to manage and is resistant to therapy. Immunotherapy is becoming a promising option for care of several types of cancers including triple negative breast cancer.
CASE REPORT: We present a case of a patient with chemo-refractory metastatic metaplastic-type of breast cancer with failures to 3 active lines of chemotherapy. The patient achieved a complete and sustained response to chemo-immunotherapy combination with acceptable tolerability and minimal adverse events. The treatment was a combination of anti-PD-L1 antibody (durvalumab) immunotherapy in combination with the chemotherapeutic agent, paclitaxel.
CONCLUSIONS: This is the first case reporting the successful use of durvalumab and paclitaxel combination for treatment of triple negative breast cancer in general, and in metastatic MPBC in specific.

Keywords: Antigens, CD274, paclitaxel, Triple Negative Breast Neoplasms